Evidence map›Paper›PMID 35243298›Full record

ReviewMaterials today. Bio2022

Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment.

Mi Zhang, Wenhui Hu, Chenhui Cai, Yu Wu, Jianmei Li, Shiwu Dong

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
58.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 1 synthesis or guideline pooled it, 366 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Application and prospects of nanomaterials in osteoporosis treatment.International journal of pharmaceutics: X · 2026
    Review
  19. Review
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mi ZhangDepartment of Biomedical Materials Science, College of Biomedical Engineering, Third Military Medical University, Chongqing, 400038, China.
Wenhui HuDepartment of Biomedical Materials Science, College of Biomedical Engineering, Third Military Medical University, Chongqing, 400038, China.
Chenhui CaiDepartment of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Yu WuDepartment of Biomedical Materials Science, College of Biomedical Engineering, Third Military Medical University, Chongqing, 400038, China.
Jianmei LiDepartment of Biomedical Materials Science, College of Biomedical Engineering, Third Military Medical University, Chongqing, 400038, China.
Shiwu DongDepartment of Biomedical Materials Science, College of Biomedical Engineering, Third Military Medical University, Chongqing, 400038, China.
Army Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory arthritis is a major cause of disability in the elderly. This condition causes joint pain, loss of function, and deterioration of quality of life, mainly due to osteoarthritis (OA) and rheumatoid arthritis (RA). Currently, available treatment options for inflammatory arthritis include anti-inflammatory medications administered via oral, topical, or intra-articular routes, surgery, and physical rehabilitation. Novel alternative approaches to managing inflammatory arthritis, so far, remain the grand challenge owing to catastrophic financial burden and insignificant therapeutic benefit. In the view of non-targeted systemic cytotoxicity and limited bioavailability of drug therapies, a major concern is to establish stimuli-responsive drug delivery systems using nanomaterials with on-off switching potential for biomedical applications. This review summarizes the advanced applications of triggerable nanomaterials dependent on various internal stimuli (including reduction-oxidation (redox), pH, and enzymes) and external stimuli (including temperature, ultrasound (US), magnetic, photo, voltage, and mechanical friction). The review also explores the progress and challenges with the use of stimuli-responsive nanomaterials to manage inflammatory arthritis based on pathological changes, including cartilage degeneration, synovitis, and subchondral bone destruction. Exposure to appropriate stimuli induced by such histopathological alterations can trigger the release of therapeutic medications, imperative in the joint-targeted treatment of inflammatory arthritis.

Indexed as

ACLT, anterior cruciate ligament transectionADAMTS, a disintegrin and metalloproteinase with thrombospondin motifsAIA, adjuvant-induced arthritisAMF, alternating magnetic fieldAPCs, antigen-presenting cellsBBR, berberineCaP, calcium phosphateCartilage degenerationCAT, catalaseCD44, cluster of differentiation 44CEL-PRNPs, RGD-modified PLGA enzyme-responsive nanoparticles loaded with tripterineCEL, tripterineCIA, collagen-induced arthritisCTSK, cathepsin KDCF, diclofenacDex/Oxi-α CDNPs, 4-phenylborate-cyclodextrin biomaterial loaded with dexamethasoneDEX-P, dexamethasone sodium phosphateDMARDs, disease-modifying anti-rheumatic drugsDMM, destabilization of medial meniscusECM, extracellular matrixELP, elastin-like peptideERK1/2, extracellular signal-regulated kinase 1/2FLSS, fibroblast synovial cellsfMRI, focusing magnetic resonance imagingGPX, glutathione peroxidaseGSH, glutathioneHA, hyaluronic acidHIFU, high intensity focused ultrasoundHM, hollow microsphereIBU, ibuprofenIGF-1, insulin-like growth factor-1IL-1Ra, interleukin-1 receptor antagonistIL, interleukinInflammatory arthritisKAFAK, KAFAKLAARLYRKALARQLGVAAK/BxN, the T cell receptor transgene KRN and the MHC class II moleculeKGN, kartogeninLDH, lactate dehydrogenaseLPS, lipopolysaccharideMAPK, mitogen-activated protein kinaseMFGCN, methotrexate-loaded folate-conjugated glycol chitosan nanoparticlesMHC, major histocompatibility complexMMPs, matrix metalloproteinasesMNPs, multifunctional nanoparticlesMOF, metal-organic frameworkMPEG-PPF, methoxy polyethylene glycol-polypropylene fumarateMP-HANPs, mineralized nanoparticlesMRI, magnetic resonance imagingMTX, methotrexateNADPH, nicotinamide adenine dinucleotide phosphateNFATc1, nuclear factor of activated T cell cytoplasmic 1NGPEGSS, nanoparticles with degradable disulfide crosslinksNIR, near-infraredNO, nitric oxideNP-gel, nanoparticle-hydrogel hybrid systemNP, nanoparticleNrf2, nuclear factor erythroid 2-related factor 2NSAIDs, non-steroidal anti-inflammatory drugsOA, osteoarthritisPAMAM, poly (Ninylisobutyramide)PCA, protocatechuic acidPDEPT, pre-enzyme drug therapyPDT, photodynamic therapyPEG-PLGA-Au, polyethylene-glycol polylactic-glycolic acid gold-containing nanoparticlesPEOx-PPOy-PEOz, poly (ethylene oxide)-block-poly (Oxypropylene)-block-poly (ethylene oxide)PEVS, platelet-derived extracellular vesiclesP-HA, polyethylene glycol hyaluronic acidPICsomes, polyion complex vesiclesPLCG1, phospholipase C gamma 1PLGA, polylactic-glycolic acidPMEOMA, poly [2-(2-methoxyethoxy) ethylmethacrylate]PNC, bisphosphonate-modified nanocellulosePNIPAM, poly (N-isopropyl acrylamide)PON1, paraoxonase-1POxs, poly (2-oxazoline)PPS, polyphenylene sulfidePTH, parathyroid hormonePTT, photothermal therapyQ, a tripeptide sequence QAWRANKL, nuclear factor-kappa B ligandRA, rheumatoid arthritisRedox, reduction-oxidationRFA, radiofrequency thermal ablationRGD, arginine-glycine-aspartic acidRMTQ, RGD-MMP-TAT-QAW peptideROS, reactive oxygen speciesSBC, sodium bicarbonateSOD, superoxide dismutaseSPION, superparamagnetic iron oxide nanoparticlesStimuli-responsive drug delivery systemSubchondral bone destructionSynovitisTATQ, TAT-QAWTA, triamcinolone acetonideTAT, transcription-transactivatingT, cell-penetrating peptideT cell, thymus cellTG-18, triglycerol monostearateTIMP, tissue inhibitor of metalloproteinaseTNF, tumor necrosis factorTolDex, tolerogenic dendritic cell-derived exosomesTR1, type 1 regulatoryUS, ultrasoundVEGF, vascular endothelial growth factorβ-TCP, β-tricalcium phosphate

Identifiers

PMID35243298
PMCPMC8881671
OpenAlexW4212826067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.